Opendata, web and dolomites

LapIt SIGNED

Making AML treatment a clinical reality: A novel anti-IL7 receptor antibody to deliver Lap to 5LO positive cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "LapIt" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 150˙000.00

Map

 Project objective

Acute Myeloid Leukemia (AML), a cancer of the myeloid line of blood cells, is the most common type of leukemia in adults (~350.000 new cases yearly worldwide), yet continues to have the lowest overall survival rate of all leukemias (26.9%). The disease is characterized by clonal expansion of undifferentiated myeloid precursors, leading to anomalous hematopoiesis and bone marrow failure. Current AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT) with treatment costs up to €300k per patient. Although some AML patients respond to chemotherapy and HSCT, most patients that go into remission show disease relapse (up to and 70%). In addition, minimal advances have been made for patients unable to tolerate intensive treatment, mostly representing older patients. This presses the need for new AML treatments that are (1) more effective and (2) tolerated by all patients. In LapIt, we will further develop a novel treatment strategy for AML, based on targeting a macromolecular target that is marker of poor prognosis for AML patients with the drug Lap. Importantly, to guarantee specific uptake of Lap by AML cells and minimize side effects to healthy cells, the drug will be further developed as an antibody-drug conjugate targeting a validated receptor which is overexpressed in AML and other leukemias. As such, our drug will not only be more effective than currently used AML therapies, but will also be tolerated by patients unable to tolerate intensive treatments. With our proposed drug candidate we are able to make, for the first time, AML treatment a clinical reality for any AML patient.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LAPIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LAPIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

NeuroMag (2019)

The Neurological Basis of the Magnetic Sense

Read More  

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  
lastchecktime (2022-10-07 1:52:21) correctly updated